v3.25.3
Consolidated Statements of Cash Flows (Parenthetical) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Disclosure of detailed information about borrowings [Line Items]    
Income tax paid € (1,355) € (1,434) [1]
Interest paid (206) (320) [1]
Interest received 170 261 [1]
Dividends received from non-consolidated entities 5 0 [1]
Net change in short-term debt and other financial instruments [2],[3] 3,322 5,876 [1]
Cash and cash equivalents [3] 15,359 6,795 [1]
Opella    
Disclosure of detailed information about borrowings [Line Items]    
Cash and cash equivalents 667  
Commercial paper program in USA    
Disclosure of detailed information about borrowings [Line Items]    
Net change in short-term debt and other financial instruments € 3,353 € 6,060
[1] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2] For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for €3,353 million, compared with €6,060 million in the six months ended June 30, 2024. This line item also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.
[3] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.